Pause operations: company temporarily curtailing operations while keeping return options open

Leave Suspension

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. On February 5, 2020, the company announced management changes effective from April 1, 2020.

 
 

Pause operations: company temporarily curtailing operations while keeping return options open

Leave Suspension
Revenue(RF), mln.USD
324
Assets(RF), mln.USD
249
Capital(RF), mln.USD
44
Glob.Revenue, mln.USD
9861
Staff(RF), 2021
126
Taxes(RF), mln.USD
1
The Company Statement
December 22, 2023

Suspended new clinical trials in Russia. Astellas halts antibiotics production in Russia. In a significant development, Astellas, a leading Japanese pharmaceutical company, has decided to halt the production of its antibiotics, Vilprafen and Vilprafen Solutab (Josamycin), in Russia. This decision has instigated a scarcity of these drugs within Russian pharmacies, with virtually no supplies available in Moscow. 24.02.2022: One of the two legal entities (ASTELLAS PHARMA JSC) was liquidated.

Open the Statement
Statements Archive
January 08, 2024Astellas explains decision on Wilprafen production in Russia
January 05, 2024LLC "ASTELLAS PHARMA PRODUCTION" - Moscow - ASTELLAS PHARMA PRODUCTION LLC - Executive Director Garin N.N. - Taxpayer Identification Number 7709948951
February 24, 2022JSC "ASTELLAS PHARMA" - Moscow - JSC "ASTELLAS PHARMA" - General Director Ferkovich V.V. - TIN 7705042683
Share the Company Status:
All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Company statements and statistical data are collected from open sources and official registers according to the methodology of the KSE Institute.
Scanner